As CAR-NK immunotherapy strongly relies on the effective migration of these cells towards the tumor, Müller et al. (2015) [249] compared the function of EGFRvIII-specific CAR-NK cells with similar CAR-NK cells that were also engineered to contain the CXCR4 chemokine receptor. Here, CXCR4 is linked to neoplasm.